Skip to main content

Table 4 Temporal trends in dossier evidence inclusion and characteristics

From: A study of the value of requesting information from drug manufacturers for systematic reviews; 9 years of experience from the drug effectiveness review project

  DERP II DERP III DERP IV
Proportion of SRs with dossier data 11/21 (52%) 7/10 (70%) 7/9 (78%)
Proportion of total dossier evidence 68/160 (42.5%) 50/160 (31.3%) 42/160 (26.3%)
Studies vs supplemental evidence
 Studies 60 37 26
 Supplemental evidence 8 13 16
Study quality
 Good 4 (6.7%) 1 (2.7%) 4 (15.4%)
 Fair 43 (71.7%) 33 (89.2%) 20 (76.9%)
 Poor 13 (21.7%) 3 (8.1%) 2 (7.7%)